Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predict S.P.A. Class B ( (IT:PRE) ) has provided an update.
Predict S.p.A. has announced its participation in the KT&Partners Annual Investors Summit Day 2025, aiming to engage with institutional and professional investors to present its business model, financial results, and growth strategies. This participation underscores Predict’s commitment to fostering dialogue with the financial community, potentially enhancing its market positioning and stakeholder engagement.
The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.
More about Predict S.P.A. Class B
Predict S.p.A., founded in 2008 in Bari, is an innovative SME in the healthcare sector, focusing on in vivo diagnostics through ultrasound and radiological equipment distribution, breath analysis technologies, and digital healthcare solutions. The company operates through four Strategic Business Units, offering products like Mistral for non-invasive oncological screening, Aphel for AI-assisted patient support, and Optip for remote medical consultations, establishing partnerships with leading Italian research institutes.
Average Trading Volume: 40,438
Technical Sentiment Signal: Hold
For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.